Currently Viewing:
The American Journal of Managed Care November 2018
A Randomized, Pragmatic, Pharmacist-Led Intervention Reduced Opioids Following Orthopedic Surgery
David H. Smith, PhD, RPh; Jennifer L. Kuntz, PhD; Lynn L. DeBar, PhD, MPH; Jill Mesa; Xiuhai Yang, MS; Jennifer Schneider, MPH; Amanda Petrik, MS; Katherine Reese, PharmD; Lou Ann Thorsness, RPh; David Boardman, MD; and Eric S. Johnson, PhD
Understanding and Improving Value Frameworks With Real-World Patient Outcomes
Anupam B. Jena, MD, PhD; Jacquelyn W. Chou, MPP, MPL; Lara Yoon, MPH; Wade M. Aubry, MD; Jan Berger, MD, MJ; Wayne Burton, MD; A. Mark Fendrick, MD; Donna M. Fick, RN, PhD; David Franklin, BA; Rebecca Killion, MA; Darius N. Lakdawalla, PhD; Peter J. Neumann, ScD; Kavita Patel, MD, MSHS; John Yee, MD, MPH; Brian Sakurada, PharmD; and Kristina Yu-Isenberg, PhD, MPH, RPh
Currently Reading
From the Editorial Board: Glen D. Stettin, MD
Glen D. Stettin, MD
Cost of Pharmacotherapy for Opioid Use Disorders Following Inpatient Detoxification
Kathryn E. McCollister, PhD; Jared A. Leff, MS; Xuan Yang, MPH, MHS; Joshua D. Lee, MD; Edward V. Nunes, MD; Patricia Novo, MPA, MPH; John Rotrosen, MD; Bruce R. Schackman, PhD; and Sean M. Murphy, PhD
Overdose Risk for Veterans Receiving Opioids From Multiple Sources
Guneet K. Jasuja, PhD; Omid Ameli, MD, MPH; Donald R. Miller, ScD; Thomas Land, PhD; Dana Bernson, MPH; Adam J. Rose, MD, MSc; Dan R. Berlowitz, MD, MPH; and David A. Smelson, PsyD
Effects of a Community-Based Care Management Model for Super-Utilizers
Purvi Sevak, PhD; Cara N. Stepanczuk, MPP; Katharine W.V. Bradley, PhD; Tim Day, MSPH; Greg Peterson, PhD; Boyd Gilman, PhD; Laura Blue, PhD; Keith Kranker, PhD; Kate Stewart, PhD; and Lorenzo Moreno, PhD
Predicting 30-Day Emergency Department Revisits
Kelly Gao; Gene Pellerin, MD; and Laurence Kaminsky, PhD
Patients' Adoption of and Feature Access Within Electronic Patient Portals
Jennifer Elston Lafata, PhD; Carrie A. Miller, PhD, MPH; Deirdre A. Shires, PhD; Karen Dyer, PhD; Scott M. Ratliff, MS; and Michelle Schreiber, MD
Impact of Dementia on Costs of Modifiable Comorbid Conditions
Patricia R. Salber, MD, MBA; Christobel E. Selecky, MA; Dirk Soenksen, MS, MBA; and Thomas Wilson, PhD, DrPH
Hospital Cancer Pain Management by Electronic Health Record–Based Automatic Screening
Jinyoung Shin, MD, PhD; Hyeonyoung Ko, MD, MPH; Jeong Ah Kim, BS; Yun-Mi Song, MD, PhD; Jin Seok Ahn, MD, PhD; Seok Jin Nam, MD, PhD; and Jungkwon Lee, MD, PhD

From the Editorial Board: Glen D. Stettin, MD

Glen D. Stettin, MD
Nobody intends to get addicted to opioids. Sadly, it happens far too often. More sadly, it is easier to get addicted than to get unaddicted.

Americans are 4.8% of the world’s inhabitants, yet we consume a highly disproportionate share of many commercially available opioids, including hydrocodone (99.7%), oxycodone (69%), morphine (49.6%), hydromorphone (45%), and fentanyl (29%). We consume more than 5 times as many daily doses as Europeans, and our use has quintupled since the 1990s.

Americans overconsume opioids for several reasons. Culturally, and I generalize, we believe pain should be treated. We believe drugs are better than nondrug treatments and opioids are better than nonopioids. Our preferences, fueled by marketing budgets of opioid manufacturers, nudged us to seek opioids for pain and our physicians to oblige. Easy access to prescription opioids made getting addicted easy.

There is good news. America’s consumption of prescription opioids has been declining since 2012. During this time, pharmacy benefit managers have expanded efforts to accelerate this trend. For example, the CDC’s revised opioid prescribing guidelines in 2017 were quickly implemented by Express Scripts to reduce unsafe use of prescription opioids. We focused on making better decisions—fewer and smaller prescriptions; safer dosing, formulations, and combinations—the easiest decisions for physicians, pharmacists, and patients. We implemented coverage policies to curtail overuse and ensure needed access. We provided patients with education, monitoring, counseling, and safe in-home disposal of unused opioids. As a result, first-time users’ average day supply per fill declined by 55%, from 18.6 to 8.3 days, and 93% of first-time fills are now for 7 days or less. And 78% of new users with initial prescriptions for long-acting opioids are redirected to safer, short-acting opioids.

But let us not fool ourselves. We have more to do to prevent and treat opioid addiction. We must advocate for solutions that eliminate unsafe opioid exposure and improve access to effective addiction treatment. Practices can set defaults and prompts in electronic prescribing systems to increase adherence to prescribing guidelines. Examples include defaulting initial prescriptions to a 3-day supply and prompting physicians to reconsider requests for long-acting opioids in opioid-naïve patients, regimens that exceed dosing guidelines, and unsafe combinations of opioids with benzodiazepines or muscle relaxants. Policy makers can improve prescription drug monitoring programs and require that prescribers use them. For people struggling with addiction, we need safer and more effective ways to help them transition off of opioids completely or onto maintenance therapies. Finally, we need easier access to naloxone for preventing overdose deaths.

Our work in preventing and treating opioid addiction may never be complete, but it will be increasingly successful if we continue to focus on making it harder to get addicted and making it easier to get unaddicted or, at least, easier to get maintenance treatment that restores dignity and function to those who got addicted despite their best intentions.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up